New Strategies Sought to Pay for Costly Cures

As Congressional leaders and White House policymakers assess a range of measures designed to manage or reduce outlays for prescription drugs, pharma companies and other stakeholders are weighing innovative reimbursement models for new therapies promising to cure or treat serious illnesses. Payer Powered by WPeMatico Continue reading New Strategies Sought to Pay for Costly Cures

Securing a Winning Strategy for Real-World Evidence

While the increasing importance of real-world evidence (RWE) is widely acknowledged, the dramatic shift required by biopharma companies to embed and secure an RWE capability effectively across the organization is still a work in progress In Deloitte s Second Annual Real-World Powered by WPeMatico Continue reading Securing a Winning Strategy for Real-World Evidence